Business
PetLife Pharmaceuticals Holds First Medical Professional Investor Conference
PetLife Pharmaceuticals Holds First Medical Professional Investor Conference.
About this update from Petlife Pharmaceuticals Inc
[{"type":"text","content":"\n\n Hancock, MD, Aug. 01, 2016 (GLOBE NEWSWIRE) -- PetLife Pharmaceuticals, Inc. (OTCQB: PTLF) a developer of a new generation of high potency veterinary cancer medications and nutraceuticals for pets, held its first investor conference for medical professionals in Maryland.\n Dr. Ralph Salvagno, CEO of Petlife Pharmaceuticals, presented an introduction to Petlife’s “Escozine for PetsTM”, a patented, polarized bio-active peptide extracted from the Blue Scorpion (Rhopularus Princeps). “It was a wonderful opportunity to present Petlife Pharmaceuticals to my medical  colleagues. The turnout was great and I am very pleased at the reception to our investment opportunity. Based upon my own research and talking to scientists , veterinarians and pet owners I am confident that we are providing a solution to a unmet need in Veterinary Oncology. What better audience is there to challenge my confidence… the toughest of audiences …my own medical colleagues. The people who have the medical background to evaluate our science and the comfort to challenge a colleague in their beliefs and commitment are the people that I invited to kick off our first Investor Conference.   I’m pleased that we were able to engage in serious and successful discussions about how Petlife Pharmaceuticals plans to change the paradigm of treatment in the care of our companion animals afflicted with cancer. Medical professionals also have the business acumen to evaluate the financial part of our investment offering as well and were presented our 506 Private Placement Memorandum (available only to accredited investors ) for their consideration.” Concluding the conference, Dr. Salvagno stated “ The reception of my colleagues to our Company and our investment opportunity has left me even more confident that Petlife is on to something big”. Petlife plans to participate in the San Francisco Money Show: August 23-25, 2016. Petlife’s 506 Private Placement Memorandum is available only to accredited investors. About PetLife Pharmaceuticals, Inc. PetLife Pharmaceuticals (OTCQB: PTLF) (http://www.PetLifePharma.com) is a registered US Veterinary Pharmaceutical company, incorporated in 2012. PetLife has developed and is launching a new generation of high potency veterinary cancer medications and nutrace...